ES2638190T3 - Métodos para tratar la dependencia - Google Patents
Métodos para tratar la dependencia Download PDFInfo
- Publication number
- ES2638190T3 ES2638190T3 ES08797300.4T ES08797300T ES2638190T3 ES 2638190 T3 ES2638190 T3 ES 2638190T3 ES 08797300 T ES08797300 T ES 08797300T ES 2638190 T3 ES2638190 T3 ES 2638190T3
- Authority
- ES
- Spain
- Prior art keywords
- dependence
- compound
- substance
- induced
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title abstract description 8
- 229940126062 Compound A Drugs 0.000 abstract description 33
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract description 33
- 208000024891 symptom Diseases 0.000 abstract description 19
- 208000022497 Cocaine-Related disease Diseases 0.000 abstract description 13
- 206010013654 Drug abuse Diseases 0.000 abstract description 9
- 206010013663 drug dependence Diseases 0.000 abstract description 7
- 201000001272 cocaine abuse Diseases 0.000 abstract description 6
- 201000006145 cocaine dependence Diseases 0.000 abstract description 6
- YZZVIKDAOTXDEB-SNVBAGLBSA-N 4-(aminomethyl)-3-[(2r)-5,7-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-1h-imidazole-2-thione Chemical compound NCC1=CNC(=S)N1[C@H]1CC2=CC(F)=CC(F)=C2CC1 YZZVIKDAOTXDEB-SNVBAGLBSA-N 0.000 abstract 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 208000011117 substance-related disease Diseases 0.000 description 27
- 239000003795 chemical substances by application Substances 0.000 description 26
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 26
- 239000000126 substance Substances 0.000 description 22
- 229960003638 dopamine Drugs 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 208000028017 Psychotic disease Diseases 0.000 description 15
- 208000026251 Opioid-Related disease Diseases 0.000 description 14
- 230000036961 partial effect Effects 0.000 description 14
- 229960003920 cocaine Drugs 0.000 description 13
- 231100000572 poisoning Toxicity 0.000 description 12
- 230000000607 poisoning effect Effects 0.000 description 12
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 11
- 229960002748 norepinephrine Drugs 0.000 description 11
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 11
- 201000005040 opiate dependence Diseases 0.000 description 11
- 201000006152 substance dependence Diseases 0.000 description 11
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 10
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 10
- 229940025084 amphetamine Drugs 0.000 description 10
- 229960002715 nicotine Drugs 0.000 description 10
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 10
- 201000009032 substance abuse Diseases 0.000 description 10
- 231100000736 substance abuse Toxicity 0.000 description 10
- 230000008033 biological extinction Effects 0.000 description 9
- 208000019901 Anxiety disease Diseases 0.000 description 8
- 208000019022 Mood disease Diseases 0.000 description 8
- 241000208125 Nicotiana Species 0.000 description 8
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 8
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 8
- 235000019788 craving Nutrition 0.000 description 8
- 230000002459 sustained effect Effects 0.000 description 8
- 206010012239 Delusion Diseases 0.000 description 7
- 208000004547 Hallucinations Diseases 0.000 description 7
- 206010057852 Nicotine dependence Diseases 0.000 description 7
- 208000025569 Tobacco Use disease Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 231100000868 delusion Toxicity 0.000 description 7
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 7
- 229950010883 phencyclidine Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 210000005240 left ventricle Anatomy 0.000 description 6
- 230000002085 persistent effect Effects 0.000 description 6
- 241000218236 Cannabis Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010022998 Irritability Diseases 0.000 description 5
- 238000011292 agonist therapy Methods 0.000 description 5
- 210000003710 cerebral cortex Anatomy 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 210000003975 mesenteric artery Anatomy 0.000 description 5
- 208000019116 sleep disease Diseases 0.000 description 5
- 206010002942 Apathy Diseases 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 206010012218 Delirium Diseases 0.000 description 4
- 241001539473 Euphoria Species 0.000 description 4
- 206010015535 Euphoric mood Diseases 0.000 description 4
- 201000001880 Sexual dysfunction Diseases 0.000 description 4
- 239000000674 adrenergic antagonist Substances 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 4
- 229960000623 carbamazepine Drugs 0.000 description 4
- 150000003943 catecholamines Chemical class 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 231100000872 sexual dysfunction Toxicity 0.000 description 4
- 208000020685 sleep-wake disease Diseases 0.000 description 4
- 208000029197 Amphetamine-Related disease Diseases 0.000 description 3
- 206010010219 Compulsions Diseases 0.000 description 3
- 208000003863 Marijuana Abuse Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 3
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 3
- 230000016571 aggressive behavior Effects 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 229960001058 bupropion Drugs 0.000 description 3
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 229940125532 enzyme inhibitor Drugs 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 229960001848 lamotrigine Drugs 0.000 description 3
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000000966 norepinephrine reuptake Effects 0.000 description 3
- -1 olanzepine Chemical compound 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 3
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 3
- 229960004394 topiramate Drugs 0.000 description 3
- 229940102566 valproate Drugs 0.000 description 3
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 2
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 2
- 229940123257 Opioid receptor antagonist Drugs 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229940121359 adenosine receptor antagonist Drugs 0.000 description 2
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 2
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 2
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000003420 antiserotonin agent Substances 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 201000001843 cannabis dependence Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 206010021654 increased appetite Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960001797 methadone Drugs 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 239000004050 mood stabilizer Substances 0.000 description 2
- 229940127237 mood stabilizer Drugs 0.000 description 2
- 239000003401 opiate antagonist Substances 0.000 description 2
- 229960001816 oxcarbazepine Drugs 0.000 description 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 208000007100 phencyclidine abuse Diseases 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 210000002254 renal artery Anatomy 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000003727 serotonin 1A antagonist Substances 0.000 description 2
- 229940125794 sodium channel blocker Drugs 0.000 description 2
- 239000003195 sodium channel blocking agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- YFMPSMITLLBENU-UHFFFAOYSA-N 3,4-dihydroxybenzylamine Chemical compound NCC1=CC=C(O)C(O)=C1 YFMPSMITLLBENU-UHFFFAOYSA-N 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 1
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 1
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- 102000008146 Acetate-CoA ligase Human genes 0.000 description 1
- 108010049926 Acetate-CoA ligase Proteins 0.000 description 1
- 101150051188 Adora2a gene Proteins 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 229940099362 Catechol O methyltransferase inhibitor Drugs 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 102000010906 Cyclooxygenase 1 Human genes 0.000 description 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010016059 Facial pain Diseases 0.000 description 1
- 229940122459 Glutamate antagonist Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229940122439 Hydroxylase inhibitor Drugs 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000001271 Inhalant Abuse Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 229940086616 Monoamine oxidase B inhibitor Drugs 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 description 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 description 1
- 102100037346 Substance-P receptor Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 102000010861 Type 3 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037543 Type 3 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000028505 alcohol-related disease Diseases 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 201000002472 amphetamine abuse Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 238000011952 auditory verbal learning test Methods 0.000 description 1
- 229960000794 baclofen Drugs 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000009322 cannabis abuse Diseases 0.000 description 1
- 229960004205 carbidopa Drugs 0.000 description 1
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- ODQWQRRAPPTVAG-BOPFTXTBSA-N cis-doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)\C2=CC=CC=C21 ODQWQRRAPPTVAG-BOPFTXTBSA-N 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960000647 gepirone Drugs 0.000 description 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 229960004002 levetiracetam Drugs 0.000 description 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960001344 methylphenidate Drugs 0.000 description 1
- 229960001785 mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 238000002670 nicotine replacement therapy Methods 0.000 description 1
- 239000000181 nicotinic agonist Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 201000000988 opioid abuse Diseases 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- YYPWGCZOLGTTER-MZMPZRCHSA-N pergolide Chemical compound C1=CC=C2[C@H]3C[C@@H](CSC)CN(CCC)[C@@H]3CC3=CN=C1[C]32 YYPWGCZOLGTTER-MZMPZRCHSA-N 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 1
- 229950009626 ritanserin Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229960005318 vigabatrin Drugs 0.000 description 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93532307P | 2007-08-06 | 2007-08-06 | |
| US935323P | 2007-08-06 | ||
| US95655507P | 2007-08-17 | 2007-08-17 | |
| US956555P | 2007-08-17 | ||
| US96059107P | 2007-10-04 | 2007-10-04 | |
| US960591P | 2007-10-04 | ||
| PCT/US2008/072357 WO2009021055A1 (en) | 2007-08-06 | 2008-08-06 | Methods for treating dependence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2638190T3 true ES2638190T3 (es) | 2017-10-19 |
Family
ID=40341713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08797300.4T Active ES2638190T3 (es) | 2007-08-06 | 2008-08-06 | Métodos para tratar la dependencia |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20090041800A1 (https=) |
| EP (2) | EP2182804B1 (https=) |
| JP (5) | JP2010535801A (https=) |
| CN (2) | CN101815438A (https=) |
| AU (1) | AU2008283903B2 (https=) |
| BR (1) | BRPI0815089A2 (https=) |
| CA (1) | CA2695372C (https=) |
| CO (1) | CO6260015A2 (https=) |
| ES (1) | ES2638190T3 (https=) |
| IL (1) | IL257418A (https=) |
| MX (4) | MX2010001390A (https=) |
| NZ (1) | NZ583192A (https=) |
| PH (1) | PH12015502210A1 (https=) |
| RU (1) | RU2491067C2 (https=) |
| SG (2) | SG10201705968RA (https=) |
| WO (1) | WO2009021055A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010001390A (es) * | 2007-08-06 | 2010-08-02 | Synosia Therapeutics Inc | Métodos para el tratamiento de dependencia. |
| WO2010124089A2 (en) * | 2009-04-22 | 2010-10-28 | Synosia Therapeutics, Inc. | Methods for treating dependence |
| US9804149B2 (en) * | 2012-10-10 | 2017-10-31 | Bio-Rad Laboratories, Inc. | Patient-based results display |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9192570B2 (en) | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US20170235908A1 (en) * | 2015-11-15 | 2017-08-17 | Oriah Behaviorial Health, Inc. | Systems and Methods for Managing and Treating Substance Abuse Addiction |
| US11844859B2 (en) | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| US11331270B2 (en) | 2017-08-20 | 2022-05-17 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| CN108066355A (zh) * | 2017-12-28 | 2018-05-25 | 宁夏恩多芬科技有限公司 | Nitrous Oxide作为治疗神经官能症的用途 |
| FR3093419B1 (fr) * | 2019-03-08 | 2021-06-18 | Univ Grenoble Alpes | Composition et procédé associé de mesure de l’observance thérapeutique |
| KR20220009954A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법 |
| JP7422473B2 (ja) * | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
| WO2021168133A1 (en) | 2020-02-19 | 2021-08-26 | Nevakar Inc. | Isoproterenol compositions and methods |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| KR20230071131A (ko) * | 2020-08-17 | 2023-05-23 | 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 | 도파민 기능의 바이오마커로서 뉴로멜라닌-민감성 mri의 용도 |
| CN116391128B (zh) * | 2020-10-24 | 2025-11-21 | 巴塞尔大学医院 | 人血浆中麦角酸二乙基酰胺（lsd）和2,3-二氢-3-羟基-2-氧代麦角二乙胺（o-h-lsd）的定量方法 |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| CN112690771B (zh) * | 2020-12-09 | 2022-05-24 | 华南理工大学 | 一种利用线性回归模型的人脸视频心率检测方法 |
| JP2024510080A (ja) | 2021-03-11 | 2024-03-06 | テラン バイオサイエンシズ インコーポレイテッド | バイオマーカーを含む撮像データセットのハーモナイゼーションのためのシステム、デバイス及び方法 |
| CN113017632B (zh) * | 2021-03-17 | 2022-11-11 | 陈思 | 一种智慧校园心理咨询辅助方法及系统 |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| JP2025530849A (ja) | 2022-09-16 | 2025-09-17 | 江▲蘇▼▲亞▼虹医▲薬▼科技股▲フン▼有限公司 | ネピカスタット酸付加塩の多形形態、その調製方法及びその使用 |
| WO2024178082A2 (en) * | 2023-02-22 | 2024-08-29 | Freedom Biosciences, Inc. | Composition of opioid receptor modulator and mdma for use thereof |
| CN120754106B (zh) * | 2025-09-02 | 2025-12-09 | 合肥工业大学 | 化合物sch23390在制备治疗铅中毒药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03500411A (ja) * | 1987-10-07 | 1991-01-31 | マトリックス テクノロジーズ インコーポレーテッド | コカイン中毒の処置および治療薬 |
| US5593367A (en) * | 1995-08-18 | 1997-01-14 | Deere & Company | Switchable ignition and starter control system |
| WO1997030977A1 (en) * | 1996-02-23 | 1997-08-28 | Pharm-Eco Laboratories, Incorporated | Selective d1 dopamine receptor agonists and partial agonists/antagonists |
| US5958896A (en) * | 1997-08-08 | 1999-09-28 | The Mclean Hospital | Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure |
| US6541520B1 (en) * | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| WO2002056964A1 (es) * | 2001-01-17 | 2002-07-25 | Hythiam, Inc. | Empleo de flumazenilo en la elaboración de una medicación para el tratamiento de la dependencia de alcohol |
| US20030040015A1 (en) * | 2001-03-07 | 2003-02-27 | Kwang-Soo Kim | Methods and reagents for identifying compounds and mutations that modulate dopamine beta-hydroxylase activity |
| SE0104388D0 (sv) * | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
| AU2004216360B2 (en) * | 2003-02-27 | 2009-09-17 | Eisai R & D Management Co., Ltd. | Pharmaceutical composition for treatment of drug dependence |
| RU2252756C1 (ru) * | 2003-12-23 | 2005-05-27 | Хохлов Александр Петрович | Препарат против алкоголизма и наркомании, способ получения такого препарата |
| WO2008115706A1 (en) * | 2007-03-16 | 2008-09-25 | Emory University | Methods and compositions for treatment of drug addiction |
| WO2009015244A1 (en) * | 2007-07-23 | 2009-01-29 | Synosia Therapeutics | Rufinamide for the treatment of post-traumatic stress disorder |
| NZ583191A (en) * | 2007-07-23 | 2012-06-29 | Biotie Therapies Inc | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder |
| JP2010534676A (ja) * | 2007-07-23 | 2010-11-11 | シノシア・セラピューティクス | 心的外傷後ストレス障害の治療 |
| MX2010001390A (es) | 2007-08-06 | 2010-08-02 | Synosia Therapeutics Inc | Métodos para el tratamiento de dependencia. |
| WO2009069669A1 (ja) | 2007-11-26 | 2009-06-04 | Bridgestone Corporation | 銅－亜鉛合金電気めっき浴およびこれを用いためっき方法 |
-
2008
- 2008-08-06 MX MX2010001390A patent/MX2010001390A/es not_active Application Discontinuation
- 2008-08-06 MX MX2015009454A patent/MX357542B/es unknown
- 2008-08-06 MX MX2018008628A patent/MX391921B/es unknown
- 2008-08-06 CA CA2695372A patent/CA2695372C/en not_active Expired - Fee Related
- 2008-08-06 US US12/187,166 patent/US20090041800A1/en not_active Abandoned
- 2008-08-06 AU AU2008283903A patent/AU2008283903B2/en not_active Ceased
- 2008-08-06 EP EP08797300.4A patent/EP2182804B1/en not_active Not-in-force
- 2008-08-06 ES ES08797300.4T patent/ES2638190T3/es active Active
- 2008-08-06 CN CN200880109939A patent/CN101815438A/zh active Pending
- 2008-08-06 SG SG10201705968RA patent/SG10201705968RA/en unknown
- 2008-08-06 RU RU2010108249/15A patent/RU2491067C2/ru active
- 2008-08-06 WO PCT/US2008/072357 patent/WO2009021055A1/en not_active Ceased
- 2008-08-06 NZ NZ583192A patent/NZ583192A/en not_active IP Right Cessation
- 2008-08-06 CN CN201611204491.7A patent/CN106983747A/zh active Pending
- 2008-08-06 JP JP2010520285A patent/JP2010535801A/ja active Pending
- 2008-08-06 EP EP17165804.0A patent/EP3251670A1/en not_active Withdrawn
- 2008-08-06 BR BRPI0815089-3A2A patent/BRPI0815089A2/pt not_active IP Right Cessation
- 2008-08-06 SG SG2012058210A patent/SG183696A1/en unknown
-
2010
- 2010-02-04 MX MX2022001510A patent/MX2022001510A/es unknown
- 2010-02-26 CO CO10023191A patent/CO6260015A2/es not_active Application Discontinuation
-
2013
- 2013-12-06 US US14/099,882 patent/US10561638B2/en not_active Expired - Fee Related
-
2014
- 2014-05-23 JP JP2014107381A patent/JP2014148551A/ja active Pending
-
2015
- 2015-09-22 PH PH12015502210A patent/PH12015502210A1/en unknown
-
2016
- 2016-08-23 JP JP2016162881A patent/JP2016210798A/ja active Pending
-
2018
- 2018-02-08 IL IL257418A patent/IL257418A/en unknown
- 2018-06-06 JP JP2018108758A patent/JP2018154645A/ja active Pending
-
2020
- 2020-01-07 US US16/736,609 patent/US20200383951A1/en not_active Abandoned
- 2020-05-01 JP JP2020081105A patent/JP2020114883A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG183696A1 (en) | 2012-09-27 |
| IL257418A (en) | 2018-04-30 |
| JP2014148551A (ja) | 2014-08-21 |
| NZ583192A (en) | 2012-06-29 |
| EP3251670A1 (en) | 2017-12-06 |
| RU2491067C2 (ru) | 2013-08-27 |
| JP2018154645A (ja) | 2018-10-04 |
| MX2022001510A (es) | 2022-08-11 |
| BRPI0815089A2 (pt) | 2014-09-30 |
| PH12015502210A1 (en) | 2017-04-10 |
| CO6260015A2 (es) | 2011-03-22 |
| EP2182804A1 (en) | 2010-05-12 |
| SG10201705968RA (en) | 2017-08-30 |
| WO2009021055A1 (en) | 2009-02-12 |
| AU2008283903B2 (en) | 2014-01-16 |
| CN101815438A (zh) | 2010-08-25 |
| MX391921B (es) | 2025-03-21 |
| CN106983747A (zh) | 2017-07-28 |
| CA2695372A1 (en) | 2009-02-12 |
| AU2008283903A1 (en) | 2009-02-12 |
| JP2016210798A (ja) | 2016-12-15 |
| EP2182804B1 (en) | 2017-05-24 |
| US20140099336A1 (en) | 2014-04-10 |
| US20200383951A1 (en) | 2020-12-10 |
| JP2010535801A (ja) | 2010-11-25 |
| MX357542B (es) | 2018-07-13 |
| CA2695372C (en) | 2013-01-22 |
| EP2182804A4 (en) | 2010-12-22 |
| US10561638B2 (en) | 2020-02-18 |
| US20090041800A1 (en) | 2009-02-12 |
| MX2010001390A (es) | 2010-08-02 |
| RU2010108249A (ru) | 2011-09-20 |
| JP2020114883A (ja) | 2020-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2638190T3 (es) | Métodos para tratar la dependencia | |
| JP2010535801A5 (https=) | ||
| PL219671B1 (pl) | Zastosowanie enancjomeru (1S, 2R) milnacypranu do wytwarzania leku | |
| RS115204A (sr) | Postupak za pomaganje prestanka pušenja | |
| JP5491475B2 (ja) | ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置 | |
| CN105473135A (zh) | 用于治疗精神症状的d-美沙酮 | |
| Hutsell et al. | Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats | |
| KR20010050225A (ko) | 포유동물에서의 니코틴 탐닉의 예방 및 치료를 위한 약학조성물 | |
| CN103442711A (zh) | 精神分裂症中的认知功能障碍的治疗方法 | |
| JP2005513105A (ja) | 臨床的うつ病を治療するためのデオキシペガニンの使用 | |
| RU2477634C2 (ru) | Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов | |
| CN101472571A (zh) | 使用毒蕈碱型受体m1拮抗剂治疗心理学病况 | |
| JP2017008044A (ja) | ドーパミンシグナル伝達の抑制剤 | |
| WO2025245102A2 (en) | Methods and compositions for treating sexual disorder, weight loss, weight maintenance, well-being, and self-esteem | |
| Nishino et al. | Pharmacology of CNS stimulants | |
| JP2016535796A (ja) | 新規な方法 | |
| Pachmerhiwala | Relationships between MDMA induced increases in extracellular glucose, glycogenolysis in brain and hyperthermia | |
| HK1155063A (en) | Treatment of post-traumatic stress disorder | |
| HK1143038A (en) | Methods for treating dependence |